Patient Corner

Latest drug updates

  • 31 Jul 2017 - Drug Updates

Daclizumab (Zinbryta▼) in multiple sclerosis: Review patients for liver function currently on treatment

Initiate daclizumab in restricted groups of patients with limited treatment options and closely monitor liver function.

Read more
  • 28 Jul 2017 - Drug Updates

Bendamustine (Levact): Increased mortality when used in combination treatment outside the approved indications

Closely monitor patients for opportunistic infections as well as cardiac, neurological, and respiratory adverse events.

Read more
  • 28 Jul 2017 - Drug Updates

Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): Risk of graft rejection

Consider the benefit of treatment with nivolumab or pembrolizumab versus the risk of possible organ transplant rejection for each patient.

Read more
  • 27 Jun 2017 - Drug Updates

Denosumab (Prolia, Xgeva▼): Risk of osteonecrosis of jaw and external auditory canal

Advise patients to report any ear pain, discharge from ear, or an ear infection during denosumab treatment.

Read more
  • 27 Jun 2017 - Drug Updates

Brimonidine gel (Mirvaso): Risk of cardiovascular events if applied to damaged skin

Advise patients not to apply brimonidine gel to irritated or damaged skin.

Read more
  • 27 Jun 2017 - Drug Updates

Restrictions to manage the risk for misuse of pseudoephedrine and ephedrine to be continued

Sale and supply of these products should be done under supervision of pharmacist or suitably trained pharmacy staff.

Read more
  • 30 May 2017 - Drug Updates

Finasteride 1 mg (Propecia): Reports of depression and suicidal thoughts in men

Advise patients to discontinue treatment immediately if episodes of depressive illness and suicidal thoughts are reported.

Read more
  • 23 Mar 2017 - Drug Updates

Pilot website to report adverse reactions of psychoactive substances

Illicit drug reaction reporting form made available for healthcare professionals,

Read more
  • 8 Mar 2017 - Drug Updates

Hyoscine butylbromide: serious adverse effects in cardiac patients

9 fatalities have been reported so far.

Read more
  • 24 Jan 2017 - Drug Updates

Apremilast (Otezla▼): risk of psychiatric symptoms

Increased risk for depression and suicidality in apremilast users.

Read more